<DOC>
	<DOCNO>NCT02277717</DOCNO>
	<brief_summary>The purpose study evaluate safety new medicinal drug SYD985 different dose level patient cancer , understand SYD985 handle body evaluate effect SYD985 cancer .</brief_summary>
	<brief_title>First-in-human Study With Antibody-drug Conjugate SYD985 Evaluate Safety Efficacy Cancer Patients</brief_title>
	<detailed_description>Cancer cell different kind protein cell surface ; one protein HER2 . HER2 play important role development cancer . High expression HER2 relate poor prognosis . Although several cancer drug available work via HER2 protein , substantial portion patient still benefit treatment . The new cancer drug SYD985 develop Synthon Biopharmaceuticals BV . SYD985 antibody-drug conjugate consist two part : antibody linker-drug moiety contain toxin . The antibody part bind HER2 surface cancer cell . When SYD985 bind cancer cell , internalize cell . After proteolytic cleavage linker , toxin split cell cancer cell kill . Thus , SYD985 consider form target chemotherapy . This first study SYD985 administer human . The study consist two part : Part I dose-escalation part low dose SYD985 give three cancer patient . If well tolerate , high dose SYD985 give 3 cancer patient . This continue dose increase safe anymore . In Part II study , several group patient specific type cancer receive SYD985 dose select evaluation . All patient part study receive SYD985 infusion every three week progression cancer unacceptable toxicity develop .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Main 1 . Patient histologicallyconfirmed , locally advanced metastatic tumor progress standard therapy standard therapy exist , follow restriction : Part I : solid tumor origin ; Part II : breast , gastric , urothelial endometrial tumor ; 2 . For Part II : HER2 tumor status define protocol ; 3 . ECOG performance status ≤ 1 ; 4 . Life expectancy &gt; 12 week ; 5 . Adequate organ function ; 6 . For Part II : measurable disease . Main 1 . Anthracycline treatment within 3 month and/or abnormal cardiac biomarker value ; 2 . Other anticancer therapy ( except LHRH agonist ) within 4 week ( 6 week trastuzumab , ( ado ) trastuzumab emtansine , nitrosoureas mitomycin C ) ; 3 . History infusionrelated reaction and/or hypersensitivity trastuzumab ( ado ) trastuzumab emtansine ; 4 . Severe , uncontrolled systemic disease ; 5 . LVEF &lt; 55 % , history absolute decrease LVEF ≥ 10 % point &lt; 50 % previous treatment trastuzumab ( ado ) trastuzumab emtansine , history decrease LVEF &lt; 40 % previous treatment trastuzumab ( ado ) trastuzumab emtansine ; 6 . History clinically significant CV disease ; 7 . Symptomatic brain metastasis , therapy brain metastasis ( exclude PCI dexamethasone treatment stable decrease daily dose ) within 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>metastasis</keyword>
	<keyword>HER2</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>duocarmycin</keyword>
	<keyword>SYD985</keyword>
	<keyword>antibody-drug conjugate</keyword>
	<keyword>ADC</keyword>
	<keyword>trastuzumab vc-seco-DUBA</keyword>
</DOC>